throbber
1 Engineering Antibodies for Therapy
`Celltech Research, Ce/ltech Ltd, Slough, UK
`
`A . MOUNTAIN AND J . R . ADAIR
`
`Introduction
`
`Antibodies have long been viewed as potential agents for targeted drug
`delivery and other therapeutic interventions, largely with a view to exploiting
`the combination of high specificity and affinity of the antibody-antigen
`interaction. Since the development of rodent monoclonal antibody (MAb)
`technology (Kohler and Milstein, 1975) it has been possible in principle to
`produce rodent MAbs to virtually any antigen, and a large number of rodent
`MAbs relevant to human therapy have been generated. MAbs have already
`been used clinically for the diagnosis and therapy of several human disorders,
`notably cancer and infectious diseases, and for the modulation of immune
`responses. The target antigens have been tumour-associated antigens (T AAs,
`Boyer et al., 1988; Herlyn, Menrad and Koprowski, 1990), specific cell type
`markers, viruses, bacteria and specific human proteins of physiological
`
`Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; bp, base pairs; BSA, bovine
`serum albumin; c[antibody name], mouse variable region-human constant region chimeric[ anti­
`body name]; ADCMC, antibody-dependent complement-mediated cytotoxicity; cDNA, comple­
`mentary DNA; CDR, complementarity determining regions; CEA, carcinoembryonic antigen;
`CTL, cytotoxic T lymphocyte; d, days; DHFR, dihydrofolatc reductase; DNS, dansyl; ELISA,
`enzyme-linked immunosorbent assay; E:T, effector-to-target ratio; HTC, fluorcsccin isothiocy­
`anate; GM-CSF, granulocyte-macrophagc-colony-stimulating factor; gpt, xanthine/guanine phos­
`phoribosyl transferase gene; h, hours; HAMA, human anti-mouse antibody; HbsAg, hepatitis B
`surface antigen; hCMV, human cytomegalovirus; hEGFR, human epidermal growth factor
`receptor; HIV, human immunodeficiency virus; hph, hygromycin B phosphotransfcrasc gene;
`HRP, horse radish peroxidase; hyg', hygromycin resistance; IC,., quantity required for 11%
`inhibition of activity; ID,., quantity of virus required for n% infection; IFNy, interferon y; i.n.,
`intra-nasal; i.p., intra-peritoneal; i.v., intra-venous; kbp, kilobase pairs; KLH, kcyhold limpet
`haemocyanin; LT, lymphotoxin; LTR, long terminal repeat unit; MAb, monoclonal antibody;
`MLR, mixed lymphocyte reaction; mRNA, messenger RNA; MSX, methionine sulphoximine;
`MTX, methotrexate;
`rzeo, neomycin phosphotransferase; NIP, 5-iodo-4-hydroxy-3-
`nitrophenacetyl; NP, 4-hydroxy-3-nitrophenacetyl; NP-cap, NP-caproic acid; OD,., optical
`density at rz nm;% i.d.g-1, percentage of injected dose per gram of tissue; o-PDM, N,N'-1.2-
`phcnylcnedimaleimide; PBMC, peripheral blood mononuclear cells; PC, phosphorylcholine;
`PEG, polyethylene glycol; PGK, phosphoglycerate kinase; pfu, plaque-forming units; PLAP.
`placental alkaline phosphatase; PMN, polymorphonuclcar lymphocyte: p/o, promoter/operator;
`rbs, ribosome binding site; RES, reticulo-endothelial system; rIL-2, recombinant interleukin 2;
`s.c., subcutaneous; SDM, site-directed mutagenesis; SRBC; sheep red blood cells; TAA,
`tumour-associated antigen; TNB, thionitrobcnzoate; TNP, trinitrophenyl; V11, heavy chain
`variable domain; V L> light chain variable domain.
`8iotec!mology a11d Genetic Engi11ceri11g Reviews- Vol. 10. December 1992
`0264--8725192110/l-142 $20.00 + $0.00 © lnlcrccpl Ltd. P.O. Box 716, Andover. Hampshire SPlO l YG. UK
`1
`
`1 of 142
`
`BI Exhibit 1067
`
`

`

`A. MOUNTAIN AND J.R. ADAIR
`2
`importance (particularly cytokines or their receptors). At the end of 1991
`there were 132 biotechnology-based medicines in formal clinical development
`(Pharmaceutical Manufacturers Association Report, 1992) or awaiting final
`approval from the US Food and Drugs Administration (FDA). Sixty-six of
`
`the 132 were for cancer therapy and 58 of the 132 were MAbs. Three rodent
`
`MAbs have so far been approved and launched as products: OKT3 is a naked
`MAb and has been approved by the FDA for treatment of acute kidney
`transplant rejection; OncoScint and MyoScint are Mab-isotope conjugates
`which have been approved outside the US as imaging agents for colorectal
`cancer and myocardial infarction, respectively. The human MAb 'Centoxin'
`has also been approved in Europe for treatment of septic shock. The total
`market for MAbs is presently around $330 million per annum and is estimated
`to grow approximately ten-fold by 1996. Therapeutic MAbs will account for
`most of this market.
`Although the specificity of MAbs undoubtedly gives them immense poten­
`tial in medicine, rodent MAbs are certainly not ideal therapeutic agents. The
`five most important issues and technical challenges in the development of
`MAb-based therapies are: (1) identifying MAbs of suitable affinity and
`specificity; (2) overcoming human immune responses against rodent MAbs
`and against any cell-killing agents attached to them; (3) identifying and
`
`harnessing appropriate cell-killing agents; ( 4) achieving appropriate pharma­
`
`cokinetics and biodistribution; (5) achieving economic manufacture, which is
`of particular relevance for highly engineered MAbs and for MAb-cytotoxic
`agent conjugates (as opposed to naked MAbs).
`As the above statistics indicate, a large proportion of the MAb-based
`agents presently in clinical development are for treatment of cancer and in
`this review the development of anti-cancer MAbs and MAb conjugates will
`largely be used to illustrate the approaches being taken to address the five key
`issues. The review begins with a brief description of the structure of
`antibodies and antibody genes, followed by a summary of the arguments and
`evidence relating to the importance of affinity and specificity for MAb-based
`therapies. We then briefly summarize the available clinical results with naked
`rodent MAbs. Next we describe the approaches being taken to overcome the
`immunogenicity in patients of rodent MAbs, which is certainly the most
`serious and general problem for MAb-based therapies. This section concen­
`trates largely on antibody humanization, which is the most promising solution
`to the problem. The processes developed for efficient cloning of antibody
`genes and for production of engineered whole antibodies are then described.
`This is followed by a summary of the approaches being taken to improve the
`pharmacokinetics and biodistribution of MAbs, focusing particularly on the
`development of engineered antibody fragments, and then by a summary of
`production systems being used for such fragments. The first half of the review
`is then completed by a summary of the various cell-killing strategies being
`developed for MAb-based therapies. The second half of the review is largely
`devoted to a detailed summary of the construction, expression, pre-clinical
`studies and data on efficacy and immunogenicity for engineered MAbs and
`MAb conjugates that have been used in clinical studies by the time of writing.
`
`2 of 142
`
`BI Exhibit 1067
`
`

`

`3
`Engineering antibodies for therapy
`The review finishes with some conclusions and a summary of recent advances
`in antibody technology which may lead eventually to the successors of
`humanized rodent MAbs for therapy.
`
`The structure of antibodies and antibody genes
`
`In order to understand the later sections of this review (especially those on
`antibody gene cloning and humanization) it is necessary to have some
`knowledge of the structure and organization of antibodies and their genes.
`We give a brief description here.
`Higher mammals have five classes of immunoglobulin, termed IgG, lgM,
`IgA, IgE and IgD. The structures and functions of these five classes have
`
`MAbs of therapeutic potential are of the IgG class, and have the basic
`structure shown in Figure IA. IgG antibodies have a tetrameric structure
`consisting of two identical 55 kDa glycosylated proteins (termed 'heavy
`chains') and two identical 25 kDa proteins, which are normally not glycosy­
`lated (termed 'light chains'), covalently Jinked by disulphide bridges. The
`
`been very well described by Roitt, Brostoff and Male (1987). Almost all
`proteins are organized into discrete folding domains of around 110 amino
`
`acids which are encoded in the genome on separate exons (Figures 1 B and
`1 C). Each light chain associates with and is covalently linked via a disulphide
`bridge to a cysteine in the N-terminal region of one heavy chain, and the
`C-terminal half of the heavy chains associate with each other to form a Y- or
`T-form structure. The heavy chains are also covalently linked to each other
`via disulphide bridges in the hinge domain.
`Sequence information is now available for hundreds of antibodies of many
`different species and reveals that the N-terminal domains of each chain are
`much more variable in sequence than the other domains. The N-terminal
`domains are therefore termed 'variable domains' and the others 'constant
`domains'. Three non-contiguous regions within these variable domains are
`particularly variable and are usually referred to as 'hypervariable loops' or
`'complementarity determining regions' (CDRs). This sequence variation is
`postulated to provide the variability (within these otherwise highly conserved
`proteins) which enables antibodies to recognize and bind to a very wide range
`
`of antigens (Wu and Kabat, 1970; Kabat et al., 1987). The proposal has been
`(Amit et al., 1986; Boulot et al. , 1987; Colman et al., 1987; Sheriff et al. , 1987;
`Davies et al. , 1989; Padlan et al., 1989; Tulip et al. , 1989, reviewed in Alzari et
`al., 1987; Bentley et al. , 1990; Bhat et al. , 1990; Davies, Padlan and Sheriff,
`1990 and Poljak, 1991). The variable region residues that are not part of the
`
`confirmed by structural studies, which show that the hypervariable sequences
`are (in most cases) associated on the surface of the antibody as a set of loops.
`The loops form a large surface patch and are in contact with antigen in cases
`for which structural information on the antibody-antigen complex is available
`
`CDR or loops together constitute the 'framework' of the variable region. It
`has been shown that the exons for the variable domains are assembled from a
`number of repeated gene families - V and J for the light chain and V, D and
`J for the heavy chain - by a series of recombination events during the
`
`3 of 142
`
`BI Exhibit 1067
`
`

`

`+:. ?> �
`77 "i ·�
`''"' nm "' mo "' i -
`0 c � >
`�';>,�·
`2::
`llllli
`II• /� 111
`\
`--. r
`. . · I"'
`=c11=-cH�1-=-"'�', o�o�:--�',
`:
`!:':H_ J_ Ill. :I&!
`
`
`z
`> z
`0 '-<
`�
`
`>-0
`
`
`:i::i
`
`A
`
`B
`
`c
`
`100-300 V GENES !N 7 CLUSTERS ENCOM?ASS\NG
`1-3Mb OF CHROMOSOME
`
`lllllll 111111 111111 IUll llllll 1111111
`
`!!1111
`
`5 JKMINIGENES AND 1 CONSTANT
`REGION GENE IN 4 Kb REGION
`
`//
`
`_____ llill_ I
`
`BI
`L.
`
`I
`
`
`
`DODOO u-.....1 ----.1
`
`HEAVY CHAIN
`
`100-1000 VH GENES IN 10
`INTERSPERSED SUBGROUPS
`
`AT LEAST 12 DH MINIGENES LINKED TO 4 JH MINIGENES
`AND 8 CONST ANT REGION GENES IN A 420 Kb REGION
`OH JH C
`
`L
`
`v
`
`Figure 1. Protein and gene organization of murine IgGK.
`
`1[u --=1 �',---:
`
`H
`
`CH2
`
`CH3
`
`4 of 142
`
`BI Exhibit 1067
`
`

`

`5
`
`Engineering antibodies for therapy
`development of the antibody-producing B-cell lineage. The variable region
`exon along with the signal sequence exon and the promoter/enhancer
`(involved in transcription) is then juxtaposed with the constant region gene
`family by further recombination events for subsequent expression (Figures
`JA, JB; reviewed by Alt, Blackwell and Yancopolous, 1987). The organiza­
`tion of the lg loci in mice and humans has been reviewed recently by Lai,
`Wilson and Hood (1989).
`The constant regions tend to be conserved in sequence among antibodies of
`a given species, and also to a lesser extent between species. Light chains have
`a single constant domain for which there are two gene loci, CK and Cl. .. IgGs
`have three constant domains on the heavy chains, CHl, CH2 and CH3.
`Between the CHl and CH2 domains (for IgGs) is a short proline-rich peptide
`sequence termed the 'hinge' which contains the cysteines that bridge the two
`heavy chains. IgGs also have a site in the CH2 domain for N-linked
`glycosylation, which is required for structural integrity of the antibody and for
`some of its effector functions. Sequence motifs within the CH2 and CH3
`domains are responsible for the effector functions, such as complement
`activation and binding to other cells of the immune system. In humans and
`rodents there are four different types of IgGs, termed 'isotypes', which vary
`in their spectrum of effector functions as a result of amino acid sequence
`variation in the constant regions (Burton, 1990). In humans there are a
`number of immunologically distinct variants of IgGl, 2 and 3, termed
`allotypes (Gorman and Clark, 1990). These allotypes are racially distributed,
`for example the Glm(3) marker predominates in Caucasian IgGl whereas
`Glm(l,17) predominates in Asian and Japanese individuals.
`Until the advent of recombinant DNA technology antibody fragments
`(Figure 2) were generated by proteolytic digestion. Pepsin cleaves IgGs on
`the C-terminal side of the hinge, liberating an antigen binding fragment
`referred to as the F(ab')i. Papain cleaves on the N-terminal side of the hinge
`and liberates two F( ab) fragments and a single Fe fragment. The F( ab)
`fragments have a single antigen binding site (monovalent), while the F(ab'h
`has two (bivalent). The term F(ab') means monovalent but with the hinge
`sequence also present. The heavy chain of the F(ab) or F(ab') is usually
`referred to as the Fd or Fd'. The variable domains of the heavy and light
`chains (V H and V d together comprise a fragment called the Fv. This is the
`smallest fragment which retains the full antigen binding activity of the
`monovalent antibody. Although the Fv can be obtained for some antibodies
`by proteolytic digestion of the IgG the process is very inefficient. Fvs
`dissociate into VH and V L under physiological conditions, and so are not
`useful for therapy. The single chain Fv (scFv) represents the most successful
`strategy for stabilizing the Fv. It has V H and V L linked by a short peptide
`linker (between the C-terminus of one domain and the N-terminus of the
`other) and expressed as a single polypeptide chain. It is possible to make scFv
`variants for most MAbs which retain most or all of the monovalent antigen
`binding activity of the MAb. In some cases V H alone displays significant
`antigen binding activity, an observation which has led to use of the term
`'single domain antibodies' (DAbs; Ward et al. , 1989). Molecular biology
`
`5 of 142
`
`BI Exhibit 1067
`
`

`

`6
`
`A. MOUNTAIN AND J.R. ADAIR
`procedures now allow the efficient production of the F(ab), F(ab'), F(ab'h
`and Fv, as well as novel engineered variants of these fragments and of course
`whole IgG.
`
`MAb affinity and specificity
`
`Laboratories developing MAbs for therapy usually choose the highest affinity
`MAb available because it is widely assumed that high affinity confers a
`therapeutic advantage. There is, however, very little actual experimental data
`relevant to the importance of affinity. This is largely because all comparative
`studies in patients or animal models have concerned MAbs which recognize
`different epitopes as well as having different affinities. For example compar­
`ative studies have been performed in an animal model with rodent MAbs
`which neutralize human TNF-cx as part of a programme to develop a MAb for
`treatment of septic shock, in which TNF-cx is an important mediator. Two
`mouse MAbs were compared for ability to prevent pyrexia induced in rabbits
`by human TNF-cx (R. Foulkes, personal communication). The 100-fold
`difference of the MAbs in ability to bind TNF-cx in vitro was shown to give a
`seven-fold difference in the doses required for complete neutralization. A
`similar correlation between affinity and effective dose has also been observed
`for MAbs neutralizing IL-5 (M. Bodmer, personal communication). These
`demonstrations of the importance of affinity are not quite conclusive,
`however, since the antibodies were directed to different epitopes.
`Most other relevant data concern MAbs recognizing T AAs, for which the
`affinity issue is complicated by several factors, including the tendency of such
`antigens to be shed from the tumour into the circulation, and tumour
`penetration. Circulating antigen may in some cases interfere with MAb
`localization to the antigen on the tumour, and MAbs which recognize
`different epitopes of the antigen on the tumour cells may also be differentially
`affected by the presence of circulating antigen. It has also been suggested that
`higher affinity antibodies may show poorer tumour penetration through an
`increased tendency to bind tightly to the antigen on the tumour cells close to
`the blood vessel through which the MAb gains access to the tumour. Many
`studies have been performed on the tumour localization in colorectal cancer
`patients of MAbs recognizing the TAA's carcinoembryonic antigen (CEA)
`and polymorphic epithelial mucin (PEM). For both antigens the affinities of
`the MAbs concerned have been measured and reported to be different.
`Although marked differences between the MAbs in tumour localization are
`also reported the data do not allow the effect of affinity differences on
`localization to be distinguished from differences in circulating half-life
`(conferred by differences in isotype and immune response), tumour site and
`size, tumour vascularity and permeability. Perhaps the most direct evidence
`(Schlom et al. , 1992) on the importance of MAb affinity for tumour therapy
`concerns two MAbs recognizing the T AA T AG72, which is expressed on
`several human tumour types. MAb B72.3, which binds this antigen, has been
`administered to over 1000 patients and shown to localize to about 75% of
`gastrointestinal, ovarian, prostate and breast tumours. B72.3 has gained
`
`6 of 142
`
`BI Exhibit 1067
`
`

`

`Engineering antibodies for therapy
`
`7
`
`HEAVY CHAIN
`
`Fab
`
`Hin go
`
`Chernlcally
`
`cross-linked F(ab')
`
`2
`
`Single chain Fv
`
`Fv
`
`
`
`Cross-linked Fv
`
`Bivalent
`single chain
`Fv-hlnge
`
`Bivalent
`chemically
`cross-linked
`slngle chain
`Fv-hinge
`
`Figure 2. Engineered antibody fragments.
`
`7 of 142
`
`BI Exhibit 1067
`
`

`

`A. MOUNTAIN AND J.R. ADAIR
`8
`regulatory approval as part of a colorectal cancer imaging agent called
`'OncoScint'. Recently a MAb CC49 has been characterized which binds to an
`overlapping epitope on T AG72 and which has approximately seven-fold
`greater affinity for this antigen than B72.3 (dissociation constants are
`16·2 x 10-9 and 2·5 x 10-9 M, respectively). The two MAbs have the same
`range of reactivities to normal adult tissues. The higher affinity MAb was
`clearly shown to have a greater anti-tumour effect (two- to three-fold at the
`same dose) than B72.3 when both MAbs were conjugated to the therapeutic
`radioisotope 1311 and used in tumour regression experiments in nude mice.
`Other studies in animal models have concluded that higher affinity MAbs give
`greater tumour uptake at low doses which do not saturate the antigen, but not
`at higher doses (Sung et al., 1992).
`Other relevant data concern comparisons of MAbs and MAbs conjugated
`to cytotoxic agents for ability to bind to, and kill, cancer cells in tissue culture.
`Cell killing by MAbs carrying low molecular weight cytotoxic drugs or protein
`toxins requires internalization of the conjugates and intracellular release of
`the active cytotoxic agent. A humanized variant of the MAb CTMOl , which
`binds to PEM, has been identified which has an affinity two- to three-fold
`greater than its parent murine MAb but retains the same specificity (J .R.
`Adair et al., unpublished). Calicheamicin conjugates of the humanized and
`murine forms have been compared for binding to tumour cell lines expressing
`PEM, for internalization and cell killing in vitro and for tumour regression in
`animal models. The higher affinity humanized form performs better for all
`three parameters (L. Hinman, personal communication).
`In summary, there are not yet sufficient data to demonstrate conclusively a
`general correlation between affinity and efficacy for therapeutic MAbs or
`their conjugates in animal models or in patients. Indeed, ethical consider­
`ations make it very difficult to carry out such comparisons in the clinic. Such
`demonstrations will require thorough head-to-head efficacy comparisons in
`animal models of MAbs with different affinities but which recognize the same
`epitope and have equivalent pharmacokinetics and biodistribution. Recently
`murine B72.3 and a humanized variant with a 100-fold lower affinity have
`been compared for ability to localize to tumours in mice (D. King, personal
`communication). The murine antibody showed somewhat greater localiza­
`tion. Although definitive studies on the importance of affinity remain to be
`done, it is very likely that for most therapeutic applications MAbs with
`minimum dissociation constants of 10-9 to 10-10 M will be essential to achieve
`efficacy and to permit economically realistic doses. It is therefore extremely
`important to retain at least most of the MAbs affinity for its antigen through
`the antibody engineering and conjugation procedures required to render it
`suitable for therapeutic use.
`One of the important advantages of MAbs and MAb conjugates over
`conventional low molecular weight drugs is their specificity for the target
`molecule. This is very likely to be reflected in a lower failure rate of
`therapeutic MAbs in development at the stage of toxicology. Specificity is of
`particular importance for anti-cancer MAbs because unfortunately no anti­
`gens have yet been identified which are expressed exclusively on tumour cells.
`
`8 of 142
`
`BI Exhibit 1067
`
`

`

`9
`Engineering antibodies for therapy
`This is why the term 'tumour-specific antigen' has largely been replaced by
`the more accurate 'tumour-associated antigen'. Expression of the antigen on
`normal tissues is a major potential problem for tumour therapy with MAbs
`and MAb conjugates, since it can lead to dose-limiting toxicities. It is
`therefore important when selecting such MAbs for development to include a
`step in the screening cascade which evaluates binding of the MAb to normal
`tissues. lmmuno-histochemical studies are usually performed which indicate
`the ability of the MAb to bind to tumours and to a range of normal tissues.
`MAbs can then be chosen which bind antigens that are highly expressed on
`tumours and also on a large proportion of cells within any one tumour. The
`most suitable of these MAbs will be those for which the antigen shows little
`expression on normal tissues - especially those likely to be involved in
`dose-limiting toxicities - or shows expression on a much smaller proportion
`of the cells. In some favourable cases the antigen may be expressed on
`important normal tissues but may be in a cellular location that is much less
`accessible to a therapeutic MAb in the circulation than is the antigen on the
`surface of tumour cells. The most frequent normal tissue expressing the T AA
`is of course the tissue of origin of the tumour. In many cases the T AA is much
`more highly expressed on tumour cells than on these normal cells, and this
`may be reflected in the levels of MAb uptake by tumour and normal tissues at
`relatively low doses. There are many T AAs for which it is suggested that the
`tumour form of the antigen is structurally different from that found on normal
`cells. Considerable effort is presently going into identifying MAbs recogniz­
`ing specifically the aberrantly glycosylated forms of glycosphingolipid and
`glycoprotein T AAs suggested to be present on tumour cells (Hakomori,
`1991a, b).
`A related potential problem of specificity is caused by the tendency of
`many T AAs to be shed from the tumour into the circulation. In some cases
`this circulating antigen may interfere with localization of the MAb to the
`tumour, especially at low doses. MAb-antigen complex formation in the
`circulation may cause toxicity when the MAb carries a cytotoxic agent
`through deposition of the agent in the organs of clearance of the complex. In
`one targeting study with colorectal cancer patients a particular anti-CEA
`MAb was shown to localize efficiently to 42 out of 43 tumours examined
`(Boxer et al. , 1992). In the remaining case the patient had a high level of
`circulating CEA. On the other hand the presence of circulating PEM was
`shown to increase levels of immune complexes in the circulation and to
`enhance tumour localization in colorectal cancer patients administered the
`anti-PEM antibody ICR2 (Davidson et al. , 1991). It is thus far from clear yet
`whether circulating antigen will be a general problem for cancer therapy with
`MAbs or MAb conjugates. In cases where circulating antigen is shown to
`interfere with MAb targeting, the specificity of MAbs is such that it may well
`be possible to identify and use MAbs capable of binding preferentially to the
`tumour-bound form of the antigen. The MAb CTMOl , for example, appears
`to bind preferentially to tumour-bound PEM rather than to PEM shed into
`the circulation (T. Baker, personal communication).
`
`9 of 142
`
`BI Exhibit 1067
`
`

`

`A. MOUNTAIN AND J.R. ADAIR
`10
`Clinical data with naked rodent MAbs
`
`The clinical use of naked rodent MAbs has so far largely focused on the
`treatment of cancer, and on suppression of immune responses involved in
`auto-immune disease, graft versus host disease (GVHD) and transplant
`rejection. Naked rodent MAbs have in general proven very ineffective in
`cancer therapy, with only 23 partial remissions and three complete remissions
`reported among the initial 185 patients included in 25 clinical trials (Catane
`and Longo, 1988). This is partly because most of these MAbs were not
`directed against cell surface structures with functions required for tumour cell
`proliferation, partly because HAMA responses prevented repeated adminis­
`tration, and partly because most rodent antibodies are very inefficient at
`recruiting human immune effector mechanisms. (Murine IgG2as and rat
`IgG2bs are rather more efficient in this respect than other isotypes.) Some
`partial responses have been observed in B-cell lymphoma patients treated
`with MAbs directed to B-cell lg idiotypes (Meeker et al. , 1985). The MAb
`most widely used clinically is OKT3, which binds to the CD3 antigen of the
`T-cell receptor (TCR) complex that is expressed on virtually all circulating
`T-cells. OKTI has been approved by the FDA for the treatment of acute
`renal allograft rejection on the basis of its superiority in randomized clinical
`trials (Ortho Multi-Center Transplant Study Group, 1985) over conventional,
`broad spectrum immunosuppressive agents (93% reversal of acute rejection
`episodes for OKTI compared to 75% for conventional agents). Despite being
`itself an immunosuppressive agent, murine OKT3 elicits HAMA responses in
`patients (see later), and also leads to toxicity problems arising from cytokine
`release which accompanies T-cell activation in response to binding of the
`MAb. OKTI therapy also leads to much broader immunosuppression than is
`desirable, with increased incidence of viral infections and B-cell neoplasms.
`Anti-Tac is another rodent MAb which is intended for use in clinical studies
`of renal allograft rejection and which appears much more promising. This
`MAb blocks the binding of IL-2 to the IL-2 receptor, which is expressed on
`T-cells participating in allograft rejection, in certain auto-immune disorders
`and in one type of acute T-cell leukaemia (ATL). Of 20 ATL patients treated
`with anti-Tac seven showed remission lasting from one to at least 17 months
`(Waldmann, 1989, 1991a, b). Murine anti-Tac is presently in clinical evalua­
`tion for acute allograft rejection, and has been successfully humanized (see
`below).
`
`Approaches to overcoming rodent MAb immunogenicity
`
`There is a great deal of evidence demonstrating that the administration of
`antibodies from rodents (and other species) to humans results in an immune
`response in the great majority of patients, which limits the use of such
`antibodies to one or perhaps two doses (Lind et al. , 1991, and references
`therein). For mouse antibodies the response has been termed the 'HAMA'
`(human anti-mouse antibody) response. Administration of further doses
`leads to accelerated clearance and in many cases to complete abrogation of
`
`10 of 142
`
`BI Exhibit 1067
`
`

`

`1 1
`Engineering antibodies for therapy
`efficacy. I t can also lead to allergic reactions and in severe cases to
`anaphylactic shock. Clearance of the complexes which form between the
`administered MAb and the HAMA antibodies can also occur through routes
`which deposit cytotoxic agents carried by the former in undesirable locations,
`giving toxicity in the organs of clearance or in the reticulo-endothelial system
`(RES). In some cases the HAMA titre increases with the kinetics expected of
`a secondary response, consistent with the presence of a pre-existing antibody
`with anti-mouse specificity (Schroff et al. , 1985; Shawler et al. , 1985;
`Courtenay-Luck et al. , 1987; Khazaeli et al. , 1991). Antibody detected during
`the early phase of the response tends to be directed to the Fe portion of the
`antibody, but later on reactivities outside this region - and especially to the
`variable region - can be detected. In some cases components of the response
`are directed to the antigen binding site, termed 'anti-idiotype' responses. It
`has been clearly demonstrated that HAMA interferes with tumour localiza­
`tion by anti-TAA antibodies (see for example Ledermann et al. , 1988;
`Goldenberg, Sharkey and Ford, 1987) and with the immunosuppressive effect
`of OKT3 in the course of acute allograft rejection (Chatenoud et al. , 1986).
`Most antibody-based therapies are very unlikely to achieve success with a
`single dose. The only exceptions to this are likely to be in acute indications
`such as septic shock, for which it is possible that a single dose of an anti-TNF
`or anti-ILl antibody can neutralize sufficient of these cytokines to prevent the
`serious (and usually fatal) organ damage which otherwise occurs. It is
`abundantly clear that it will not be possible in general to eradicate solid
`tumours with a single dose of an antibody or an antibody conjugate. Many
`different approaches are therefore being taken to allow repeated administra­
`tion of therapeutic antibodies. One obvious approach is to isolate and use
`human rather than foreign antibodies. Although there are some human
`antibodies presently in clinical evaluation - notably the anti-LPS antibody
`'Centoxin' for treatment of septic shock - the technology does not yet exist
`routinely to isolate human antibodies of suitable affinity and specificity.
`Recent technology developments which may eventually lead to more routine
`isolation of therapeutically useful human MAbs are summarized at the end of
`this review. In the short term the use of at least the binding site from a
`non-human antibody remains the only generally applicable method of exploit­
`ing the specificity and affinity of the antibody-antigen interaction for therapy.
`Several approaches have been suggested and attempted for overcoming the
`HAMA response to allow repeated administration of therapeutic mouse
`MAbs. One is to use conventional immunosuppressants at sub-toxic doses to
`immune response.
`reduce the patient's ability to mount an effective
`Co-treatment with corticosteroids and azathioprine, for example, was shown
`to delay and diminish the HAMA response to murine OKT3 (Chatenoud et
`al. , 1986). Similarly co-treatment with cyclosporin A was shown to reduce
`and delay the HAMA response of colorectal cancer patients treated with the
`radiolabelled anti-CEA antibody A5B7 (Ledermann et al. , 1988). The effect
`was sufficient to allow four doses of the conjugate to be administered.
`Tumour uptake of the conjugate increased with each dose in the cyclosporin
`co-treated patients but not in those who were not given the immunosuppres-
`
`11 of 142
`
`BI Exhibit 1067
`
`

`

`12
`A. MOUNTAIN AND J .R. ADAIR
`sant. Although the use of conventional immunosuppressants in these cases
`allowed more than a single administration the number of effective doses was
`still quite small. Such general immunosuppression is clearly undesirable in
`any case since it leads to the risk of infection and since the involvement of the
`patients immune system may well often be required in order to achieve cures.
`It is also possible that one consequence of general immunosuppression will be
`accelerated cancer prog

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket